EAL® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of cancer. It is a preparation of activated and expanded T cells originally taken from a patient’s autologous peripheral blood and cultured using our patented methods(Patent number: ZL200710102854.0). The main active component of the product is CD3+ CD8+ cytotoxic T cells.The efficacy of activated autologous lymphocytes (AAL) therapy (of which EAL® is an example) in the prevention of postsurgical recurrence of liver cancer has been seen in overseas clinical trials. Separately, the safety and efficacy of EAL® produced using our patented methods in the treatment of tumours have been reported in three SCI academic journal articles.
Corresponding parameter set not found, please add it in property template of background